2-bromo-4'-benzyloxy-2'-methoxyacetophenone | 143489-46-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-4'-benzyloxy-2'-methoxyacetophenone
• 英文别名: 2-bromo-1-(4-benzyloxy-2-methoxyphenyl)ethanone；2-Bromo-1-[2-methoxy-4-(phenylmethoxy)phenyl]ethanone；2-bromo-1-(2-methoxy-4-phenylmethoxyphenyl)ethanone
• CAS: 143489-46-7
• 化学式: C₁₆H₁₅BrO₃
• 分子量: 335.197
• InChiKey: YSBYLJWAZCNTIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-4'-benzyloxy-2'-methoxyacetophenone 在 吡啶 、 茴香硫醚 、 三氟乙酸 作用下， 以 乙醇 为溶剂， 反应 11.0h， 生成 2-(2-methoxy-4-methylsulphonyloxyphenyl)imidazo<1,2-a>pyrimidine
  参考文献：
  名称：

  Inotropic 2-arylimidazol[1,2-a]pyrimidines

  摘要：

  A series of 2-arylimidazo[1,2-a]pyrimidines has been prepared and evaluated for inotropic activity. Three of these heterocycles. ether 19, sulphide 21 and mesylate 24 displayed more potent inotropic effects in vitro than isomazole. The in vivo inotropic potencies of 4'-mesylate 24 and 4'-carboxamido analogue 23 were similar to those of isomazole and sulmazole respectively. The effects of some 'A' and 'C' ring substituents on the inotropic activities of the imidazo[1,2-a]pyrimidines were different from those on the imidazopyridines. Nevertheless the inotropic potencies of several imidazo[1.2-a]pyrimidines were closer to those of their 1H-imidazo[4,5-b]pyridine isomers than to those of the corresponding isomazole analogues. Structure-activity relationships are discussed in detail.

  DOI：

  10.1016/0223-5234(92)90004-k
• 作为产物：
  描述：

  1-(2-甲氧基-4-苯基甲氧基苯基)乙酮 在 2-吡咯烷酮 、 pyrrolidone hydrotribromide 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以53%的产率得到2-bromo-4'-benzyloxy-2'-methoxyacetophenone
  参考文献：
  名称：

  Inotropic 2-arylimidazol[1,2-a]pyrimidines

  摘要：

  A series of 2-arylimidazo[1,2-a]pyrimidines has been prepared and evaluated for inotropic activity. Three of these heterocycles. ether 19, sulphide 21 and mesylate 24 displayed more potent inotropic effects in vitro than isomazole. The in vivo inotropic potencies of 4'-mesylate 24 and 4'-carboxamido analogue 23 were similar to those of isomazole and sulmazole respectively. The effects of some 'A' and 'C' ring substituents on the inotropic activities of the imidazo[1,2-a]pyrimidines were different from those on the imidazopyridines. Nevertheless the inotropic potencies of several imidazo[1.2-a]pyrimidines were closer to those of their 1H-imidazo[4,5-b]pyridine isomers than to those of the corresponding isomazole analogues. Structure-activity relationships are discussed in detail.

  DOI：

  10.1016/0223-5234(92)90004-k

文献信息

• PHENYLIMIDAZOLE COMPOUNDS
  申请人：Shibutani Tadao

  公开号：US20110275823A1

  公开（公告）日：2011-11-10

  [Object] To provide a pharmaceutical product (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, etc. [Solving Means] A phenylimidazole compound represented by the following General Formula (1): wherein, R 1 represents a hydrogen atom, a phenyl lower alkyl group optionally having a substituent, or a pyridyl lower alkyl group optionally having a substituent, and the benzene ring and the pyridine ring are optionally substituted with 1 or 2 substituents selected from the group consisting of halogen atoms, cyano group and halogen-substituted lower alkyl groups. One of R 2 and R 3 represents a hydrogen atom and the other represents a lower alkoxy group. R 4 represents a phenyl group optionally having a substituent. R 5 and R 6 are the same or different, and represent a hydrogen atom or a lower alkyl group. R 7 and R 8 are the same or different, and represent a hydrogen atom or a lower alkoxy group. However, when R 1 represents an unsubstituted phenyl lower alkyl group, R 2 represents a lower alkoxy group, R 3 represents a hydrogen atom, R 4 represents a phenyl group optionally having a substituent, and R 5 represents a hydrogen atom, R 6 is not a hydrogen atom.

  提供一种在预防和治疗高脂血症、肥胖等方面有效的药物产品（化疗药物）。 解决方法是通过以下一般式（1）所代表的苯基咪唑化合物： 其中，R1代表氢原子、苯基较低烷基基团（可选地带有取代基）或吡啶基较低烷基基团（可选地带有取代基），苯环和吡啶环可选地带有来自卤原子、氰基和卤代较低烷基基团的1或2个取代基。R2和R3中的一个代表氢原子，另一个代表较低烷氧基团。R4代表可选地带有取代基的苯基团。R5和R6相同或不同，代表氢原子或较低烷基基团。R7和R8相同或不同，代表氢原子或较低烷氧基团。但是，当R1代表未取代的苯基较低烷基基团时，R2代表较低烷氧基团，R3代表氢原子，R4代表可选地带有取代基的苯基团，R5代表氢原子时，R6不是氢原子。
• PHENYLIMIDAZOLE COMPOUND
  申请人：Otsuka Pharmaceutical Factory, Inc.

  公开号：US20180354930A1

  公开（公告）日：2018-12-13

  Provided is a compound (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, or the like. A phenylimidazole compound or a pharmaceutically acceptable salt thereof represented by the following formula (1):

  提供一种化合物（化疗剂），其有效预防和治疗高脂血症、肥胖症等。该化合物为下式（1）所示的苯基咪唑化合物或其药学上可接受的盐。
• METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE
  申请人：Glaceum, Inc.

  公开号：EP3782999A1

  公开（公告）日：2021-02-24

  The present invention relates to a method for synthesizing a 3-phenyl-2,8-dihydropyrano[2,3-f]chromene derivative, which may be usefully used for synthesizing a pyranochromenyl phenol derivative, and when the derivative is used, the 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative may be effectively prepared.

  本发明涉及一种合成 3-苯基-2,8-二氢吡喃并[2,3-f]色烯衍生物的方法，该衍生物可用于合成吡喃色烯基苯酚衍生物，当使用该衍生物时，可有效地制备 3-苯基-2,3,4,8,9,10-六氢吡喃并[2,3-f]色烯衍生物。
• US8329739B2
  申请人：——

  公开号：US8329739B2

  公开（公告）日：2012-12-11
• [EN] METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE<br/>[FR] PROCÉDÉ DE SYNTHÈSE D'UN DÉRIVÉ DE 3-PHÉNYL-2,8-DIHYDROPYRANO [2,3-F] CHROMÈNE<br/>[KO] 3-페닐-2,8-디히드로피라노[2,3-F]크로멘 유도체의 합성 방법
  申请人：GLACEUM INC

  公开号：WO2019194582A1

  公开（公告）日：2019-10-10

  본 발명은 피라노크로메닐페놀 유도체의 합성에 유용하게 이용될 수 있는 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체의 합성 방법에 관한 것으로, 상기 유도체를 이용하면 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체를 효과적으로 제조할 수 있다.